FDA scientists opposed Trump administration’s move to ease peptide access
Effort to loosen rules on unproven peptide drugs, favored by RFK Jr, faced fierce pushback from agency scientists A plan to give people in the United States easier access to unproven peptide drugs favored by the US health secretary, Robert F Kennedy Jr , was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development.